

Edgar Filing: HEALTHWATCH INC - Form NT 10-Q

HEALTHWATCH INC
Form NT 10-Q
May 15, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB

OMB Number:
Expires:
Estimated average
hours per response

FORM 12b-25

SEC FILE
0-11

NOTIFICATION OF LATE FILING

(Check One): Form 10-K Form 20-F Form 11-K
 Form 10-Q Form N-SAR

CUSIP
42221

For Period Ended: March 31, 2002

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: _____

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify
the Item(s) to which the notification relates:

PART I -- REGISTRANT INFORMATION

=====

Full Name of Registrant

HealthWatch, Inc

Former Name if Applicable

Edgar Filing: HEALTHWATCH INC - Form NT 10-Q

Address of Principle Executive Office (Street and Number)

1100 Johnson Ferry Road, Suite 670

City, State and Zip Code

Atlanta, Georgia 30342

Part II -- RULES 12b25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

- | | | | |
|-----|--|-----|---|
| | | (a) | The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
| | | (b) | The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K or Form N-SAR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
| [X] | | (c) | The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |

SEC 1344 (6/94)

Part III -- NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 11-K, 10-Q, N-SAR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Company has not been able to complete the final review of its financial statements in a timely manner without unreasonable efforts and expense. Due to resource constraints, the Company will be unable to complete its review of final adjustments by the filing due date. Additional time is necessary for management to assure itself that all adjustments and efforts have been made to file with the Commission correct financial statements for this period.

Part IV -- OTHER INFORMATION

- (1) Name and telephone number of person to contact in regard to this notification

Edgar Filing: HEALTHWATCH INC - Form NT 10-Q

| | | |
|-------------------------|-------------|--------------------|
| Thomas C. Ridenour, CFO | (404) | 256-0083 |
| ----- | ----- | ----- |
| (Name) | (Area Code) | (Telephone Number) |

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes No

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

HealthWatch, Inc

 (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date May 14, 2002 By: /s/ Thomas C. Ridenour, Chief Financial Officer

 [Type in Name]

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative's authority to sign on behalf of the registrant shall be filed with the form.

ATTENTION

 Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

HealthWatch, Inc.
 EXPLANATION

Form 12b-25

Part IV (3) - Other Information

- o Significant reduction in operating expenses and net loss.